Matches in SemOpenAlex for { <https://semopenalex.org/work/W1498436457> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W1498436457 endingPage "185" @default.
- W1498436457 startingPage "185" @default.
- W1498436457 abstract "Introduction: Vancomycin, a tricyclic glycopeptides antimicrobial, usually use in treatment of serious gram positive bacterial infections has narrow therapeutic index. Presently, resistant microorganisms to vancomycin had been gradually reported, therapeutic drug monitoring (TDM) of vancomycin should be performed during treatment. According to vancomycin excretion is predominantly by glomerular filtration, the data of pharmacokinetic parameters in renal insufficient patient is necessary for prevention of adverse drug reaction and effective dosage regimen. Objectives: to study pharmacokinetic parameters of vancomycin and design the appropriate plan for TDM in end stage renal disease (ESRD) patients. Method: Retrospective study of the serum concentration of vancomycin data after receiving the first dose in patients with ESRD was performed. Then the calculated pharmacokinetic parameters from short-infusion model were used to predict the vancomycin concentrations in various times after administration to evaluate and design the appropriate plan for TDM. Results: The data of serum vancomycin concentrations from 123 ESRD patients whom received vancomycin 1 g i.v. drip in 2 hr q 96 hr at first dose were collected. The calculated pharmacokinetics parameters of vancomycin; volume of distribution, elimination rate constant, clearance, and elimination half-life were 36.57±7.21 L, 0.003 ± 0.025 hr -1 , 0.40±0.14 L/hr, 71.76 ± 32.39 hr, respectively. In addition, at 24 hr post dose, there were 52.85% and 16.26% of patients had subtherpeutic concentration according to the recommended target trough concentration of 15-20 and 10-15mg/L, respectively. Conclusion: At 24 hr after the first dose, TDM of vancomycin should be performed for designing and optimization of dosage regimen in individualized ESRD patients." @default.
- W1498436457 created "2016-06-24" @default.
- W1498436457 creator A5012680781 @default.
- W1498436457 creator A5019077913 @default.
- W1498436457 creator A5019304007 @default.
- W1498436457 creator A5021863107 @default.
- W1498436457 creator A5065700974 @default.
- W1498436457 creator A5089371264 @default.
- W1498436457 date "2014-01-01" @default.
- W1498436457 modified "2023-09-23" @default.
- W1498436457 title "Pharmacokinetic Study and Therapeutic Drug Monitoring of Vancomycin in End Stage Renal Disease Patients" @default.
- W1498436457 hasPublicationYear "2014" @default.
- W1498436457 type Work @default.
- W1498436457 sameAs 1498436457 @default.
- W1498436457 citedByCount "0" @default.
- W1498436457 crossrefType "journal-article" @default.
- W1498436457 hasAuthorship W1498436457A5012680781 @default.
- W1498436457 hasAuthorship W1498436457A5019077913 @default.
- W1498436457 hasAuthorship W1498436457A5019304007 @default.
- W1498436457 hasAuthorship W1498436457A5021863107 @default.
- W1498436457 hasAuthorship W1498436457A5065700974 @default.
- W1498436457 hasAuthorship W1498436457A5089371264 @default.
- W1498436457 hasConcept C112705442 @default.
- W1498436457 hasConcept C126322002 @default.
- W1498436457 hasConcept C139254425 @default.
- W1498436457 hasConcept C159641895 @default.
- W1498436457 hasConcept C2778063415 @default.
- W1498436457 hasConcept C2778980435 @default.
- W1498436457 hasConcept C2779489039 @default.
- W1498436457 hasConcept C2780272996 @default.
- W1498436457 hasConcept C3019040382 @default.
- W1498436457 hasConcept C523546767 @default.
- W1498436457 hasConcept C54355233 @default.
- W1498436457 hasConcept C71924100 @default.
- W1498436457 hasConcept C86803240 @default.
- W1498436457 hasConcept C98274493 @default.
- W1498436457 hasConceptScore W1498436457C112705442 @default.
- W1498436457 hasConceptScore W1498436457C126322002 @default.
- W1498436457 hasConceptScore W1498436457C139254425 @default.
- W1498436457 hasConceptScore W1498436457C159641895 @default.
- W1498436457 hasConceptScore W1498436457C2778063415 @default.
- W1498436457 hasConceptScore W1498436457C2778980435 @default.
- W1498436457 hasConceptScore W1498436457C2779489039 @default.
- W1498436457 hasConceptScore W1498436457C2780272996 @default.
- W1498436457 hasConceptScore W1498436457C3019040382 @default.
- W1498436457 hasConceptScore W1498436457C523546767 @default.
- W1498436457 hasConceptScore W1498436457C54355233 @default.
- W1498436457 hasConceptScore W1498436457C71924100 @default.
- W1498436457 hasConceptScore W1498436457C86803240 @default.
- W1498436457 hasConceptScore W1498436457C98274493 @default.
- W1498436457 hasIssue "3" @default.
- W1498436457 hasLocation W14984364571 @default.
- W1498436457 hasOpenAccess W1498436457 @default.
- W1498436457 hasPrimaryLocation W14984364571 @default.
- W1498436457 hasRelatedWork W152437147 @default.
- W1498436457 hasRelatedWork W1831522254 @default.
- W1498436457 hasRelatedWork W1892965049 @default.
- W1498436457 hasRelatedWork W1982109043 @default.
- W1498436457 hasRelatedWork W2066277746 @default.
- W1498436457 hasRelatedWork W2094377223 @default.
- W1498436457 hasRelatedWork W2096999509 @default.
- W1498436457 hasRelatedWork W2097114593 @default.
- W1498436457 hasRelatedWork W2105222639 @default.
- W1498436457 hasRelatedWork W2118254617 @default.
- W1498436457 hasRelatedWork W2137097556 @default.
- W1498436457 hasRelatedWork W2162706798 @default.
- W1498436457 hasRelatedWork W2314579645 @default.
- W1498436457 hasRelatedWork W2370318231 @default.
- W1498436457 hasRelatedWork W2391501965 @default.
- W1498436457 hasRelatedWork W2791625562 @default.
- W1498436457 hasRelatedWork W3018439210 @default.
- W1498436457 hasRelatedWork W3195332922 @default.
- W1498436457 hasRelatedWork W3200759606 @default.
- W1498436457 hasRelatedWork W2162160795 @default.
- W1498436457 hasVolume "9" @default.
- W1498436457 isParatext "false" @default.
- W1498436457 isRetracted "false" @default.
- W1498436457 magId "1498436457" @default.
- W1498436457 workType "article" @default.